At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
NurOwn (MSC-NTF cells)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS
In Brief
A Phase 2 clinical trial evaluating NurOwn (MSC-NTF cells) for Multiple Sclerosis, Chronic Progressive. Completed, enrolled 23 participants across 4 sites.
Detailed Summary
A multidose open-label study with autologous Mesenchymal Stromal Stem Cells Secreting Neurotrophic Factors (MSC-NTF cells) involving 20 participants with progressive MS at multiple investigational study sites.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Chronic Progressive
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartMar 2019
Primary CompletionMar 2021
Study CompletionMar 2021
TodayJul 2026
First PostedJan 10, 2019
Enrollment StartMar 13, 2019
Primary CompletionMar 11, 2021
Study CompletionMar 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.5 years ago
Interventions
NurOwn (MSC-NTF cells)biological
Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors